Statins for the Primary Prevention of Heart Failure in Patients Receiving Anthracycline Pilot Study

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 112 participants.

Also called NCT03186404

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 2
Enrolled
  • 112 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03186404
Other papers using this trial's data
  • Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines European heart journal. Cardiovascular pharmacotherapy, 2023-09-20 DOI, PubMed 37120736, PMC10509566 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Canada (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03186404. Randomized; quadruple masking; primary purpose prevention. Start 2018-05-10 (actual); primary completion 2021-12-21 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Statins for the Primary Prevention of Heart Failure in Patients Receiving Anthracycline Pilot Study
Acronym
SPARE-HF
Condition
Cancer
Condition
Heart Failure
Condition
Cardiotoxicity
Intervention (Drug)
Atorvastatin
Intervention (Drug)
Placebo oral tablet
Lead sponsor
University Health Network, Toronto (class: other)
Collaborator
Mount Sinai Hospital, Canada (class: other)
Collaborator
Unity Health Toronto (class: other)
Collaborator
Sunnybrook Health Sciences Centre (class: other)
Collaborator
Scarborough General Hospital (class: other)

Record details

Record id
cardio:ct-nct03186404
Content hash
36a3db0254fbe96c64722c0a63e41021915905fa0f7630b21a7398af872f9afc